Promoter holding
64.27%
LP
Lee Pharma Limited - Due diligence report
A 360° intelligence report on Lee Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - g…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Lee Pharma — 360° Intelligence Report
Generated from MCA filings & public records85/100
Trust Score
Low Risk
Lee Pharma is assessed as Low Risk with a Trust Score of 85/100. Lee Pharma is an active public limited indian non-government company incorporated in 1997, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 13 Jul 2026 from the latest processed filings. Lee Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
78/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Profitable - internal accruals available.
- Externally credit-rated (A3).
Charges position: 8 open (592.69 cr) · 36 satisfied (518.66 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Sbicap Trustee Company Limited | 1 | 48.0 cr |
| State Bank Of India | 8 | 48.0 cr |
| Others | 18 | 48.0 cr |
| Canara Bank | 4 | 48.0 cr |
| Hdfc Bank Limited | 2 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 78/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- Delayed payments to MSME suppliers disclosed (151 disclosure(s)).
- 4 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SANTOSH BABU BUSANI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VIJAYKUMAR RAGHUNANDANPRASAD AGRAWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAGHUMITRA ALLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DR GOPALA RAO TATINENI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAMASESHAPPA SIVA PRASAD PANCHANGAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANIL JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ALLA RATNA KUMARI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| VENKATA REDDY ALLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 3 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
Key managerial personnel: RAGHUMITRA ALLA (Whole-time director) · ALLA RATNA KUMARI (Whole-time director) · VENKATA REDDY ALLA (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 28+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
8 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 1.95 cr.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence84/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 8 open charge(s) of 592.69 cr already registered.
- Compliance record supports lending.
Investor view81/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
15 May 2025
Charge created
Others - 15.00 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
29 Mar 2025
Charge created
Others - 18.00 cr
22 Jan 2025
Charge satisfied
Others
30 Sep 2024
Director appointed
RAMASESHAPPA SIVA PRASAD PANCHANGAM (Director)
Director ceased
RAMASESHAPPA SIVA PRASAD PANCHANGAM
17 May 2024
Charge created
Axis Bank Limited - 12.50 cr
05 Feb 2024
Charge satisfied
State Bank Of India
02 Jan 2024
Charge created
Others - 25.00 cr
22 Nov 2023
Charge satisfied
Hdfc Bank Limited
20 Nov 2023
Charge satisfied
Others
15 Nov 2023
Charge satisfied
Canara Bank
Charge satisfied
Syndicate Bank
24 Oct 2023
Charge created
State Bank Of India - 35.30 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of A3 from Crisil.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Sudarshan Minerals | U14108RJ1999PLC015885 | Udaipur, Rajasthan, India |
| Hmel Organics Private Limited | U20119PB2023PTC059471 | T Sabo, Punjab, India |
| Punjab Chemicals | L24231PB1975PLC047063 | Derabassi, Punjab, India |
| Anupam Rasayan | L24231GJ2003PLC042988 | Surat, Gujarat, India |
| Parijat Industries | U24219DL1995PLC161189 | New Delhi, Delhi, India |
| Hemani Group | U24114MH1994PLC076416 | Mumbai, Maharashtra, India |
| Jesons | U24295MH1999PLC122193 | Mumbai, Maharashtra, India |
| Br Agrotech | L24119DL1989PLC036264 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Lee Pharma before audits and certifications: compliance score 78/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Lee Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Lee Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Lee Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Lee Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Lee Pharma an active company?
Lee Pharma has MCA status “Active” with a compliance score of 78/100 (Low Risk).
Is Lee Pharma financially healthy?
Lee Pharma has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Lee Pharma?
Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Lee Pharma?
Promoters hold a majority stake - exact percentages are in the full report. 8 active director(s) are on record.
Does Lee Pharma have loans or charges against its assets?
8 open charge(s) are registered against its assets, and 36 earlier charge(s) stand satisfied.
Is Lee Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 78/100 (Low Risk).
Is it risky to lend to Lee Pharma?
Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
